Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Accumulated Expenses: 2022-2025

Historic Accumulated Expenses for NewAmsterdam Pharma Co N.V (NAMS) over the last 2 years, with Sep 2025 value amounting to $5.9 million.

  • NewAmsterdam Pharma Co N.V's Accumulated Expenses rose 40.16% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 40.16%. This contributed to the annual value of $8.7 million for FY2024, which is 157.71% up from last year.
  • As of Q3 2025, NewAmsterdam Pharma Co N.V's Accumulated Expenses stood at $5.9 million, which was up 55.17% from $3.8 million recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's Accumulated Expenses ranged from a high of $8.7 million in Q4 2024 and a low of $1.1 million during Q1 2024.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's median Accumulated Expenses value was $3.6 million (recorded in 2023), while the average stood at $3.9 million.
  • Data for NewAmsterdam Pharma Co N.V's Accumulated Expenses shows a peak YoY spiked of 157.71% (in 2024) over the last 5 years.
  • NewAmsterdam Pharma Co N.V's Accumulated Expenses (Quarterly) stood at $2.0 million in 2022, then surged by 69.37% to $3.4 million in 2023, then spiked by 157.71% to $8.7 million in 2024, then skyrocketed by 40.16% to $5.9 million in 2025.
  • Its Accumulated Expenses was $5.9 million in Q3 2025, compared to $3.8 million in Q2 2025 and $2.0 million in Q1 2025.